

Título del Proyecto	<b>Targeted multifunctional nanoemulsions to interrupt metastasis progression</b>
Nº de expediente asignado	AC18/00045
Abstract	<p>Metastasis is the major cause of death in cancer patients with solid tumors. In Non-Small Cell Lung Cancer (NSCLC), highly metastatic locally and in distal organs, the 5-year mean survival is lower than 5% in the metastatic setting. Occult micrometastases (OM) are, by definition, small clusters of metastatic cells, and can only be detected by highly invasive molecular methods, remaining largely untreated and eventually leading to the development of overt metastases. Early detection of OM and treatment can interrupt metastasis progression and ultimately improve survival. METASTARG is an innovative solution relying on nanotechnology for the early detection and treatment of OM to cause a direct impact in patient survival, quality of life, and health-economics. METASTARG Nanoemulsions are developed to identify OM by novel characteristic targets found in metastatic cells and Interrupt Metastasis Progression (NIMPs). This unique patient-driven approach has the potential to become a gold standard in the treatment and monitoring of lung cancer.</p>
Entidad Financiadora	Instituto de Salud Carlos III (ISCIII)
Convocatoria:	EURONANOMED III "EUROPEAN INNOVATIVE RESEARCH & TECHNOLOGICAL DEVELOPMENT PROJECTS IN NANOMEDICINE" ACCIONES COMPLEMENTARIAS DE PROGRAMACION CONJUNTA INTERNACIONAL – AES 2018.
Importe de la ayuda	169.884 €
Fechas de ejecución del proyecto	01/01/2019 – 31/12/2021
	Estas ayudas están financiadas por el Instituto de Salud Carlos III y cofinanciadas por FEDER, Programa Operativo Crecimiento Inteligente 2014-2020 "Una manera de hacer Europa"



**UNIÓN EUROPEA**  
Fondo Europeo de Desarrollo Regional

*"Una manera de hacer Europa"*

Enlaces:

<http://euronanomed.net/>

<http://euronanomed.net/wp-content/uploads/2019/04/2018-METASTARG.pdf>

<https://www.linkedin.com/in/metastarg-project/>

<https://twitter.com/METASTARG>